Contineum Therapeutics
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
10578 Science Center Dr Ste 200, San Die...Phone Number
(858) 333-5280Website
www.contineum-tx.comRevenue
$50 MillionStock Symbol
CTNMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Contineum Therapeutics
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Contineum targets biological pathways associated with specific clinical disabilities, that once modulated, can demonstrably impact the course of disease.Explore more
Contineum Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Contineum Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Contineum Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Contineum Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Contineum Therapeutics has new funding data
Check out if Contineum Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Contineum Therapeutics
Contineum Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Contineum Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Contineum Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Contineum Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Contineum Therapeutics
Compare insights from companies similar to Contineum Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Contineum Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Contineum Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Contineum Therapeutics.
Contineum Therapeutics Tech Stack
A closer look at the technologies used by Contineum Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Spending/Investment, Business Finance, Clinical Operations, Finance
Person-Based
Earnings, Clinical Operations, Finance
Open Position
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Contineum Therapeutics News & Media
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company’s clinical priorities and upcoming catalysts during a presentation at the Leerink Global Healthcare Conference, emphasizing a shift from a discovery platform to a clinical-stage company with two lead programs and multiple triaA brain biotech's top drug fails against MS | BioPharma Dive
Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for a drug that’s also piqued Johnson & Johnson’s interest.Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced an update on its Phase 1b positron emission tomography (PET) trial of PIPE-791, a selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor. The Company has completed enrollment of the healthy volunteer andContineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can be accessed on the Investors section
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Contineum Therapeutics
Sign Up For FreeTo access detailed company insights
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Contineum targets biological pathways associated with specific clinical disabilities, that once modulated, can demonstr... Read More
